BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:IPH5201 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of IPH5201\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05742607-11151@assetmemo.bio
DTSTAMP:20261121T004512Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:IPH5201: Phase 2 readout est. (NCT05742607)
DESCRIPTION:IPH5201\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IPH5201
  and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MA
 TISSE)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iph5201#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05742607
URL:https://assetmemo.bio/drug/iph5201#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
